Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus
(2017) In Leukemia and Lymphoma 58(12). p.2824-2832- Abstract
Mantle cell lymphoma (MCL) is a rare, aggressive, incurable B-cell malignancy. Ibrutinib has been shown to be highly active for patients with relapsed/refractory (R/R) MCL. The RAY trial (MCL3001) was a phase 3, randomized, open-label, multicenter study that compared ibrutinib with temsirolimus in patients with R/R MCL. Active disease is frequently associated with impaired functional status and reduced well-being. Therefore, the current study employed two patient-reported outcome instruments, the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) and the EQ-5D-5L, to assess symptoms, well-being, health status, and health-related quality of life of patients on treatment within the RAY trial. We found that patients on ibrutinib... (More)
Mantle cell lymphoma (MCL) is a rare, aggressive, incurable B-cell malignancy. Ibrutinib has been shown to be highly active for patients with relapsed/refractory (R/R) MCL. The RAY trial (MCL3001) was a phase 3, randomized, open-label, multicenter study that compared ibrutinib with temsirolimus in patients with R/R MCL. Active disease is frequently associated with impaired functional status and reduced well-being. Therefore, the current study employed two patient-reported outcome instruments, the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) and the EQ-5D-5L, to assess symptoms, well-being, health status, and health-related quality of life of patients on treatment within the RAY trial. We found that patients on ibrutinib had substantial improvement in FACT-Lym subscale and total scores, and had improvement in EQ-5D-5L utility and VAS scores compared with temsirolimus patients, indicating a superior well-being. These improvements in well-being correlated with clinical response, indicating that better health-related quality of life was associated with decreased disease burden.
(Less)
- author
- organization
- publishing date
- 2017-05-30
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Bruton’s tyrosine kinase inhibitor, EQ-5D-5L, FACT-Lym, ibrutinib, mantle cell lymphoma, patient-reported outcomes
- in
- Leukemia and Lymphoma
- volume
- 58
- issue
- 12
- pages
- 2824 - 2832
- publisher
- Taylor & Francis
- external identifiers
-
- pmid:28556689
- wos:000406290000007
- scopus:85019717990
- ISSN
- 1042-8194
- DOI
- 10.1080/10428194.2017.1326034
- language
- English
- LU publication?
- yes
- id
- 7f6a61bd-c916-431b-a8d8-114b693712c1
- date added to LUP
- 2017-06-21 14:52:46
- date last changed
- 2024-10-14 08:18:12
@article{7f6a61bd-c916-431b-a8d8-114b693712c1, abstract = {{<p>Mantle cell lymphoma (MCL) is a rare, aggressive, incurable B-cell malignancy. Ibrutinib has been shown to be highly active for patients with relapsed/refractory (R/R) MCL. The RAY trial (MCL3001) was a phase 3, randomized, open-label, multicenter study that compared ibrutinib with temsirolimus in patients with R/R MCL. Active disease is frequently associated with impaired functional status and reduced well-being. Therefore, the current study employed two patient-reported outcome instruments, the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) and the EQ-5D-5L, to assess symptoms, well-being, health status, and health-related quality of life of patients on treatment within the RAY trial. We found that patients on ibrutinib had substantial improvement in FACT-Lym subscale and total scores, and had improvement in EQ-5D-5L utility and VAS scores compared with temsirolimus patients, indicating a superior well-being. These improvements in well-being correlated with clinical response, indicating that better health-related quality of life was associated with decreased disease burden.</p>}}, author = {{Hess, Georg and Rule, Simon and Jurczak, Wojciech and Jerkeman, Mats and Santucci Silva, Rodrigo and Rusconi, Chiara and Caballero, Dolores and Joao, Cristina and Witzens-Harig, Mathias and Bence-Bruckler, Isabelle and Cho, Seok-Goo and Zhou, Wenjiong and Goldberg, Jenna D and Trambitas, Cristina and Enny, Christopher and Vermeulen, Jessica and Traina, Shana and Chiou, Chiun Fang and Diels, Joris and Dreyling, Martin}}, issn = {{1042-8194}}, keywords = {{Bruton’s tyrosine kinase inhibitor; EQ-5D-5L; FACT-Lym; ibrutinib; mantle cell lymphoma; patient-reported outcomes}}, language = {{eng}}, month = {{05}}, number = {{12}}, pages = {{2824--2832}}, publisher = {{Taylor & Francis}}, series = {{Leukemia and Lymphoma}}, title = {{Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus}}, url = {{http://dx.doi.org/10.1080/10428194.2017.1326034}}, doi = {{10.1080/10428194.2017.1326034}}, volume = {{58}}, year = {{2017}}, }